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Numerous roles of astrocytes have been reported in the 
central nervous system. Astrocytes have the potential to exist 
in two states, the reactive and the resting states. Reactive 
astrocytes have morphological features such as the increase in 
thickness, number of processes and volume of cell body. 
Molecular changes also occur, such as an increase in the 
expression of glial fibrillary acidic protein (GFAP). However, 
the morphological and molecular dynamics during the memory 
formation in astrocytes remain largely unknown. Moreover, 
the pathophysiological roles of the reactive state of astrocytes 
are thought to be of importance in the pathogenesis of 
neurodegenerative diseases, including Alzheimer’s disease 
(AD). However, the detailed mechanisms underlying the 
transition of astrocytes from the resting state to the reactive 
state during neurodegenerative disease largely remain unclear. 
Here, I investigated the changes in astrocytes in the 
hippocampus of Fvb/n mice trained with contextual fear 
conditioning to memory induction, and the morphological and 
molecular dynamics were analyzed in astrocytes. One hour 
after fear conditioning, type II and type III astrocytes 
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displayed a unique status, not reactive nor resting state, with 
an increased the number of processes and decreased GFAP 
expression. In addition, the protein level of excitatory amino 
acid transporter 2 (EAAT 2) was increased at 1 hour to 24 
hours after fear conditioning while EAAT1 did not show any 
changes. Connexin 43 protein expression was found to be 
increased at 24 hours after fear conditioning test. After L-α-
aminoadipate treatment, an astrocyte-specific toxic molecule, 
mice showed the impairment of cognitive function. In addition, 
I investigated which pathways are involved in activating 
astrocytes from the resting state to the reactive state in an AD 
context such as JAK/STAT3, MAPK, NF-kB, and NFAT in 
primary cultured astrocytes treated with oligomeric amyloidβ
peptide (oAβ) and in the hippocampus of 5XFAD mice. 
Treatment with oAβinduced an increase in reactive astrocytes, 
as assessed by the protein expression of GFAP and this 
increase was caused by signal transducer and activator of 
transcription 3 (STAT3) phosphorylation in primary cultured 
astrocytes. The treatment with Stattic, an inhibitor of STAT3 
phosphorylation, rescued the activation of astrocytes in 
primary cultured astrocytes. Additionally, the systemic 
administration of Stattic rescued the activation of astrocytes 
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in the hippocampus of 6-month-old 5XFAD mice as well as 
impairments of cognitive function. Collectively, these results 
demonstrated that the status of astrocytes transit into a novel 
state, memory induction state, by hippocampus-based 
contextual memory process. These astrocytes in the memory 
induction state are thought to be not induced in 5XFAD mice 
brains, because astrocytes exist in the reactive state in the 
hippocampus of 5XFAD mice. Reactive astrocytes in the brains 
of 5XFAD mice were found to be induced via STAT3 
phosphorylation and the impairments in learning and memory 
observed in the 5XFAD mice are rescued by the inhibition of 
STAT3 phosphorylation, suggesting that the inhibition of 
STAT3 phosphorylation in astrocytes may be a novel 
therapeutic target for cognitive impairment in AD. 
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Morphology of astrocytes 
Astrocytes were named from its star-shaped morphology and 
represent the most abundant cell type in mammalian brains [1]. 
Astrocytes have complex spongiform with many processes [2]. 
These processes are classified based on the size and location, 
branches and branchlets are the first and second processes, 
respectively. Leaflets are peripheral fine processes of which 
processes cannot be imaged in light microscopy. End feet of 
astrocytes contact with blood vessels and synapses [3]. Single 
astrocyte contacts with over 2 million synapses [4]. In humans, 
astrocytic complexity is higher than rodents. Intelligence 
might be involved the astrocytic complexity [5].  
Astrocytes are classified by the morphology such as fusiform, 
elongated and spherical cell [6]. Type I astrocytes display a 
higher morphological complexity as short and numerous 
processes. Type II astrocytes display an elongated and bipolar 
shape. Type III astrocytes display the star shape with GFAP 
staining [7].  
 
Function of astrocytes 
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Astrocytes are well known for their various functions what 
they serve within the CNS such as metabolic energy support 
[8-10], maintenance of extracellular ionic homeostasis [11-
13], modulation of neurotransmitter actions [14-16] and 
protection of the CNS from peripheral system via the blood-
brain barrier [9, 17, 18]. In addition to these well-known roles 
of astrocytes, bidirectional communication between astrocytes 
and neurons has been shown to regulate neuronal excitability 
and synaptic transmission and plasticity [19-21]. Recent 
studies are extensively focusing on the roles of astrocytes in 
synaptic formation and neurogenesis [10, 22, 23], and in 
supporting learning and memory formation [24, 25].  
 
Gliotransmitter of astrocytes 
Astrocytes release  gliotransmitters such as glutamate, D-
serine, GABA and ATP, which bind to the receptors on 
synapses to modulate neuronal firing frequency and synaptic 
transmission [26, 27]. Alterations of gliotransmitter release-
related proteins such as vesicular transporters, vesicle-
associated membrane proteins and release channels cause 
brain disorders and abnormal behaviors [28, 29]. The 
molecular mechanisms governing gliotransmitter release have 
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not been fully elucidated. The unknown extracellular signals 
induce the intracellular calcium level via the inositol 1,4,5 
triphosphate-mediated calcium release from the endoplasmic 
reticulum [26, 30, 31]. These increased intracellular calcium 
levels spread out other astrocytes through gap-junction 
proteins, called ‘calcium waves’ [32, 33]. The increased 
intracellular calcium levels activate gliotransmitter release 
such as glutamate, D-serine and ATP from astrocytes, which 
is called calcium-dependent gliotransmitter release [34-36]. 
The uptake and release of each gliotransmitter through 
exocytotic vesicles are mediated by vesicular glutamate 
transporter (VGLUT) [37], vesicular D-serine transporter 
(VSERT) [38] and vesicular nucleotide transporter (VNUT) 
[30]. These gliotransmitters are released via P2X receptor 
[39], the cell swelling-induced anion transporter and such 
hemichannels as connexin 43 (Cx43) [40]. 
 
Glutamate uptake transporters of astrocytes 
Astrocytes regulate synaptic transmission to modulate 
excitotoxicity by glutamate uptake via excitatory amino acid 
transporters (EAATs) [41]. EAAT1 is known as glutamate 
aspartate transporter 1 (GLAST-1) [42] and EAAT2 is known 
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as glutamate transporter 1 (GLT-1) [43]. Both EAAT1 and 
EAAT2 are predominantly expressed on astrocytes to uptake 
glutamate from synapses [44]. Specifically, EAAT2 is 
responsible for approximately 90% of total glutamate uptake 
[45, 46]. EAAT3, 4 and 5 are expressed on the axon terminal, 
postsynaptic membrane and dendrite [47]. 
 
Modulate synaptic plasticity by astrocytes 
D-Serine, a gliotransmitter, moderates synaptic plasticity as a 
physiological coagonist of the N-methyl-D-aspartate-type 
glutamate receptor (NMDAR), a key neurotransmitter receptor 
[48]. D-Serine released from astrocytes activates NMDAR in 
neurons. NMDAR synaptic potentials and long-term 
potentiation (LTP) are reported to be regulated by D-serine in 
the hippocampus [49, 50]. 
 
Synaptogenesis by astrocytes  
Thrombospondins (TSPs), a family of 5 extracellular matrix 
proteins, secreted from astrocytes serve as synaptogenic 
factors [51]. Treatment with TSP promotes the formation of 
synapses, but these synapses are not fully functional. Because 
these synapses that are newly formed by TSP do not express 
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α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
type glutamate receptors (AMPARs), these receptors are 
nonfunctional [52]. In addition, other astrocyte-derived 
factors, such as secreted protein acidic, enriched in cysteine 
(SPARC) and hevin are reported to control synapse formation. 
SPARC and hevin are highly expressed during the early stage 
of mouse development [53]. Hevin regulates the formation of 
glutamatergic synapses by serving as a bridge between 
presynaptic neurexin-1 α (NRX1 α) and postsynaptic 
neuroligin-1B (NL1B) [54]. Furthermore, astrocytes promote 
neuronal differentiation and proliferation by IL-1β, IL-6, 
WNT3 and neurogenesis by IL-6 but suppress neuronal 
differentiation and proliferation by decorin, IGFBP6 and 
enkephalin [55]. 
 
JAK / STAT pathway 
STAT3 protein belongs to the seven-membered STAT 
family (1-7). STAT is the transcription factors to respond to 
transmitting signals form surface receptors. Cytokines, 
growth factors and hormones binding to respective receptors 
activate STAT pathway. STAT family serves important roles 
such as angiogenesis, immune response, cell proliferation and 
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survival [56, 57].  
 
Structure of STAT3 
STAT3 is the most studied among the seven STAT family 
members. STAT3 is expressed in many organs as lung, liver, 
pancreas, heart, skeletal muscle, kidney, placenta and brain 
[58]. STAT3 consists of the N-terminal domain, coiled-coil 
domain, DNA-binding domain, linker region, Src homology 2 
(SH2) domain and C-terminal transactive domain [59, 60]. 
The coiled-coil domain attends to the initiation of gene 
expression. The SH2 domain attend to stabilize STAT3-
STAT3 dimerization and STAT3-receptor interaction. These 
dimerized STAT3 bind to DNA motif and initiate gene 
transcription [61].  
 
Phosphorylation of STAT3 
Janus tyrosine kinases (JAKs) attend to phosphorylation of 
cell surface receptors as JAK-STAT pathway. STAT3 is 
recruited to phospho-tyrosine residues of the activated 
receptor through SH2 domain [62]. STAT3 is phosphorylated 
at tyrosine 705 [63]. Phosphorylated STAT3 promotes dimer 
formation and translocation into the nucleus [64].  
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Hyperactivation of STAT3 has been reported in tumors such 
as brain cancer, breast cancer, liver cancer, lung cancer, 
kidney cancer, prostate cancer, ovary cancer and multiple 
myeloma [65-70]. Additionally, STAT3 phosphorylation 
promotes cancer metastasis as migration and invasion via 
Twist, vimentin, Snail and matrix metalloproteinase 2 
(MMP2)[71].  
Immune responses are reported to be altered by STAT3 
activation. STAT3 affects the gene expression to upregulate 
interukin-6 (IL-6) and 10 (IL-10), and to downregulate 
interferons, IL-12, cluster of differentiation 80 (CD80), CD86, 
C-C motif ligand 5 (CCL5) and C-X-C motif chemokine ligand 
10 (CXCL10) [72]. 
 
Classification of reactive astrocytes 
Recently, it has been reported that reactive astrocytes are 
classified by genetic expression patterns as A1-type and A2-
type [73, 74]. A1-type reactive astrocytes show neurotoxic 
effects such as decreasing synaptic functions and astrocytic 
phagocytic capacity [75]. A1-type reactive astrocytes are 
activated by LPS or microglia-derived IL-1 α, TNF α and C1q 
[73].  A1- type reactive astrocytes have specific genetic 
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expression, such as H2T23, Serping1, H2D1, Ggta1, Iigp1, 
Gbp2, Fbln5, Ugt1a, Fkbp5, Psmb8, Srgn and Amigo20. A2-
type reactive astrocytes display neuroprotective effects, such 
as neuronal survival and tissue repair. A2-type reactive 
astrocytes have specific genetic expression profiles, such as 
the increases in Clcf1, Tgm1, Ptx3, S100a10, Sphk1, Cd109, 
Ptgs2, Emp1, Sic10a6, Tm4sf1, B3gnt5 and Cd14 [73]. 
 
Alzheimer’s disease 
The first discovery of Alzheimer’s disease (AD) is attributed 
to Alois Alzheimer, a German neurologist at the beginning of 
the 20th century (1906). Auguste Deter who was the first 
patient diagnosed as AD was suffering with continuous 
memory and language problems at 55-year-old. The patient’s 
autopsy revealed neuritic plaques and neurofibrillary tangles 
[76, 77]. In further research, neuritic plaques are identified as 
the aggregation of amyloidβpeptide (Aβ) [78, 79]. 
Additionally, glial cells such as astrocytes and microglia are 
activated and found around neuritic plaques [80, 81]. AD is 
caused by the aberrant processing of amyloid precursor protein 
(APP) and accumulation of Aβ[82]. APP is processed byβ-site 
APP cleaving enzyme1 (BACE1) and γ-secretase to produce 
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Aβ[83]. Additionally, the genetic mutations on APP and / or 
presenilin 1 (PS1) promote the early onset of AD [84, 85].  
However, AD is a complex disease with a multifactorial 
etiological view. AD cases present less than 1% in familial 
form and the heritability is estimated up to 60 – 80% in 
monozygotic twins [86]. 
 Oligomeric form of Aβdiffuses into synapses and affect the 
abnormal synaptic signaling and the activity of kinases [87]. 
In addition, aggregated Aβleads to hyperphosphorylation of 
the microtubule-associated tau protein in neurons [88]. The 
polymerization of phosphorylated tau (p-tau) aggregates into 
neurofibrillary tangles inside neurons [89]. 
AD is an extremely complex and progressive 
neurodegenerative disease. Age is a major risk factor for AD 
[90]. However, it is not enough to fully account for AD [91]. 
Other risk factors of AD such as cardiovascular risk factor, 
brain trauma, hypertension, insulin resistance, obesity, 
metabolic syndrome, inflammation and apolipoprotein gene E4 
alleles have been suggested [92, 93]. Furthermore, the whole 
etiology of the AD is still not elucidated. Several hypotheses 
suggested various causative factors such as Aβ accumulation, 
tau hypophosphorylation, acetylcholine deficiency, brain-
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derived neurotrophic factor (BDNF) deficit, mitochondrial 
dysfunction and other factors [94]. Many compounds are tested 
to AD clinical trials to target anti-Aβ, anti-tau, anti-
neuroinflammation and neuroprotection [95].  
 
AD drugs 
However, unfortunately, most of AD drug candidates have been 
failed in clinical trials. Donepezil, galantamine, rivastigmine, 
tacrine and memantine are the only used FDA-approved drugs 
for AD, to date [96]. Various candidate drugs targeting AD by 
various methods have been tested in clinical trials or have 
failed [97]. Triptolide extract, punicalagin, WIN, 2-AG and 
methanandamide are natural phytochemical cannabinoid 
agonists [98-100]. Pelargonidine, Bambusea Concretio 
Salicea and monascin are endogenous antioxidant factors [101, 
102]. Resveratrol (in Phase 1 of clinical trial), tocoteienol, 
anthocyanins (in Phase 2), epicatechin and 3H-1,2-ditheiole-
3-thione are exogenous antioxidant compounds [103, 104]. 
Penicillin, sephalosporin, ampicillin, estrogen (in Phase 2), 
riluzole (in Phase 2) and insulin (in Phase 1) are stimulators 
of GLT1 expression [105]. Pyridazone and LDN/OSU-0212320 





















Morphological changes and synaptic invasion of astrocytes are 
known to be required for controlling synaptic strength [20]. 
However, morphological or molecular changes of astrocytes 
during learning and memory processes still remain to be 
elucidated.  
According to previous reports, astrocytes are classified based 
on their morphology such as cell body size, the number of 
processes, thickness of processes, direction of processes or 
length of processes into type I, II and III. Type I astrocytes 
have a small cell body size and numerous short processes, type 
II astrocytes have a bipolar shape and long processes. Type III 
astrocytes are characterized by a star shape and long processes 
[107-109]. The morphological characteristics of astrocytes 
are thought to be important for their functions [107, 109]. 
However, each type of astrocyte is classified by its 
morphological characteristics, but the different functions, 
genetic expression and protein markers of each type of 
astrocytes have not been determined [110, 111].  
Contextual fear conditioning test has been exploited to test 
hippocampus-dependent memory in rodents [112-114]. Fvb/n 
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mice were subjected to contextual fear conditioning test, and 
checked for morphological and molecular changes in 
astrocytes at 1 hour and 24 hours after contextual fear 
conditioning. After fear conditioning test, type II and type III 
astrocytes exhibited a unique status with an increased number 
of processes and decreased protein level of GFAP and 
increased level of EAAT2 and Cx43 protein which differs from 
the typical resting or reactive state. 
These results showed that hippocampus-based contextual 
memory processes results in changes in the status of 
astrocytes towards a novel status different from typical resting 
or reactive states. These morphological and molecular 
changes may be in line with functional changes of astrocytes. 
In this study, I aimed to examine time-dependent 
morphological and/or molecular changes in astrocytes based 
on the hypothesis that astrocytes play critical roles in memory 
formation accompanied by morphological, molecular and 
functional changes.   
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MATERIALS AND METHODS 
 
1. Reagents and antibodies 
RNA and protein isolation kit were purchased from 
NucleoSpin (#740933.50, Macherey-Nagel, Dűren, Germany) 
and Pierce™ BCA Protein Assay Kit were purchased from 
Thermo (#23227, MA, USA). Anti-GFAP, rabbit polyclonal 
antibody was purchased from DAKO (#Z0334, CA, USA). Anti-
Iba1, rabbit polyclonal antibody was purchased from WAKO 
(#016-20001, Osaka, Japan). Anti-mouse, sheep polyclonal 
horseradish peroxidase (HRP) tagged antibody was purchased 
from Abcam (#ab26116, #ab26113 and #ab6808, EA, UK). 
Anti-EAAT2 rabbit monoclonal antibody was purchased from 
Cell signaling (#3838, MA, USA). Anti-Cx43 mouse 
monoclonal and anti-EAAT1 antibodies were purchased from 
Santacruz (#sc-59949 and #sc-15316, Taxas, USA). Anti-
NeuN rabbit monoclonal antibody was purchased from 
Millipore (#3838, MA, USA). Anti-GAPDH, rabbit polyclonal 
antibody was purchased from AbFrontier (#LF-PA0018, Seoul, 
Korea). Anti-PSD-95, mouse monoclonal antibody and anti-
rabbit, goat polyclonal tagged Alexa fluor 488 and 4’, 6-
diamidino-2-phenylinodole (DAPI) were purchased from 
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ThermoFisher (#MA1-046, #A11034, #A11012 and #D3571, 
MA, USA).  
 
2. Experimental animals 
 FVB/N mice were obtained from Central Laboratory Animal 
Incorporation (Seoul, Korea) and the 6 to 8-week-old male 
mice were used for the experiments. The mice were housed in 
group of five per cage with a 12 h light/dark cycle and ad 
libitum access to food and water as under standard laboratory 
housing condition.  
 
3. Contextual fear conditioning 
Contextual fear conditioning was performed as described 
previously [115, 116]. Each scrambler was connected to an 
electronic constant-current shock source that was controlled 
via an interface connected to a Windows 7 computer running 
EthoVision XT 8 software (Noldus Information Technology, 
VA, USA). A digital camera was mounted on the steel ceiling 
of each chamber, and video signals were sent to the same 
computer for analysis. Prior to training, mice were placed into 
the chamber for 60 min for habituation. During training, mice 
were placed in the conditioning chamber (13 × 13 × 25 cm) 
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for 3 min (for pre-shock) and received three repetitions of a 
foot-shock (0.7 mA, 2 sec) at 1 min inter-trial intervals. On 
the next day, conditioned mice were placed in the same 
chamber, and the “ freezing ”  time was measured over 
periods of 3 min. Conditioned freezing was defined as 
immobility except for respiratory movements. The total 
freezing time in the test period was represented as a 
percentage. Animals were divided into 2 groups. The sham 
control group (control group) did not receive electric foot 
shocks even though all other the fear conditioning procedures 
were the same as the test group. The test group was exposed 
to contextual fear conditioning with electric foot shock on day 
2.   
 
4. Western Blotting 
For brain tissue preparation, mice were deeply anesthetized 
with Zoletil (12.5 mg/kg) and Rompun mix (17.5 mg/kg) 
administered intraperitoneally. Mice were perfused 
transcardially with heparin dissolved in PBS (pH 7.2). The 
dissected brain tissues were frozen at -80°C for Western 
blotting. Tissues were homogenized with total RNA and 
protein isolation with NucleoSpin RNA/Protein kit. The 
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protein samples were quantified with Pierce™ BCA Protein 
Assay Kit and 50 μg protein sample were used for each 
Western blot. The primary antibodies were applied in the 
following concentrations: anti-GFAP (rabbit, 1: 1,000), anti-
Iba1 (rabbit, 1:300), anti-EAAT1 (rabbit, 1:1,000, anti-
EAAT2 (rabbit, 1:1,000), anti-Cx43 (mouse, 1:1,000), anti-
PSD95 (mouse, 1:2,000), anti-NeuN (mouse, 1:1,000), anti-
GAPDH (rabbit, 1:10,000). Secondary antibodies were 
conjugated with horse-radish peroxidase (HRP) (1: 2,000). 
The HRP signals were visualized using an enhanced 
chemiluminescent (ECL, Abfrontier) substrate. 
 
5. Immunohistochemistry  
Brains were perfused transcardially with heparin dissolved in 
PBS (pH 7.2) for 5 min. Brains were fixed in a 4 % 
paraformaldehyde in PBS for 24 h at 4°C and incubated in 30 % 
sucrose solution for 48 h at 4°C. For immunohistochemical 
experiments, brain tissues were coronal sectioned 30 μm with 
a Crystat (Cryotome, Thermo Elctron Corporation, MA, USA) 
and stored in cryoprotection solution at 4°C. For antigen 
retrieval, brain sections were incubated with 10mM sodium 
citrate (pH 8.5) in an 80°C water bath for 30 min. Brain 
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sections were then blocked with 0.3 % triton X-100, 2 % horse 
serum and 2 % BSA in PBS for 1 hour. The anti-GFAP (rabbit) 
antibody was applied at a concentration of 1: 1,000. Secondary 
antibodies were applied in the following concentrations; anti-
rabbit-488 (goat, 1:200) and 1 μM DAPI. Sections were 
mounted in microscope slides in a mounting solution. Confocal 
microscopic observation was performed using LSM 510. 
 
6. Analysis of Astrocytes morphology 
 Sholl analysis was performed to investigate the changes in 
astrocytes morphology as previously described [117]. 
Astrocytes were stained with anti-GFAP antibody in the 
hippocampal dentate gyrus and the images were obtained 
every 1μm interval between 0 to 30 μm depth with Z-Stack 
system using LSM 510 confocal microscope. Confocal Z-stacks 
were reconstructed in 3-D using LSM software and sholl 
analysis was performed with the 3-D reconstructed confocal 
image. Concentric circles with 10 um diameters were drawn 
from the center of the cell body of an astrocyte. Processes 
intersecting the concentric circles were manually counted at 
each distance from the cell body by adobe Photoshop CC 2014. 




7. Stereotaxic surgery for LAA injection  
 Stereotaxic surgery was performed as described previously 
[118]. All the mice were deeply anesthetized with isoflurane. 
LAA (20 μg) was bilaterally injected via a Hamilton syringe 
into the dentate gyrus of the hippocampus. (AP - 1.5, ML ± 
1.4, DV - 3.1 at a rate of 0.15μ m/min up to 1μl) 
 
8. Statistical analysis 
 Data are expressed as the mean ± SEM (means ± standard 
error of the mean). One-way ANOVA followed by Fisher’s 
LSD post-hoc analysis or Students’ t-test (SPSS, IL, USA) 
was performed to determine statistical significance. The 













1. Fvb/n mice were exposed to contextual fear conditioning 
I performed contextual fear conditioning for expressing 
hippocampus-dependent long-term spatial memory. 
Generally, a conditioned stimulus and an unconditioned 
stimulus are used for this behavior test. However, I employed 
a contextual fear conditioning test without a sound cue,  
because I aimed to focus only on the hippocampus-dependent 
memory. A schematic time-schedule of the fear conditioning 
test we used in this study is shown in Fig. 1-1a. 
It was confirmed that at intervals between the 1st and 2nd 
electric shocks (1/2), the 2nd and 3rd (2/3) and after the 3rd 
electric shocks (3/E), the mice displayed increased freezing 
behavior. These results indicate that the mice were well-
trained by the fear conditioning (Fig. 1-1b). At day 3, the 
freezing time of the control and the test group mice were 
analyzed. The test group exhibited a significantly increased 
freezing time, compared to the control group (Fig. 1-1b). 
These data indicated that contextual fear memory was induced 
by contextual fear conditioning protocol.  
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2. Alterations in astrocytic morphological characteristics 
were observed in the hippocampal dentate gyrus after 
contextual fear conditioning in Fvb/n mice  
Confocal images of hippocampal slices from the 2 group mice 
were taken with Z-stack at 0 ~ 30 μm by 1 μm interval and 
reconstructed into 3-D images. The number of intersections 
between astrocyte processes and concentric circles were 
manually counted. 
In humans, patients with amnestic mild cognitive 
impairment show shape and volume changes in the CA3 and 
dentate gyrus of the hippocampus [119]. Therefore, the 
dentate gyrus is one of the important regions for long-term 
memory and was chosen as the focus of this study. Type I 
astrocytes were found to constitute only a small percentage of 
astrocytes in the dentate gyrus (data not shown). The 
intersections of type II astrocytes and thus the processes of 
these cells, were significantly increased at 15μm from the 
cell body at 1 hour but not at 24 hours after fear conditioning 
was performed. At 20μm, the number of intersections were 
significantly increased at both 1 hour and 24 hours. At 25μm, 
the number of intersections was significantly increased at 1 
hour (Fig. 1-2b).  
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   The intersections of type III astrocytes were significantly 
increased at 10μm from the cell body at 1 hour but not at 24 
hour. At 15 μm, the number of intersections was significantly 
increased at 1 hour but not at 24 hour. At 20 μm, the number 
of intersections was also significantly increased at 1 hour but 
not at 24 hour. At 25μm, the number of intersections was 
significantly increased at 1 hour but not at 24 hour. At 30μm, 
the number of intersections was significantly increased at 1 
hour but not at 24 hour (Fig. 1-2b). These data indicate that 
hippocampues-dependent memory induction causes the 
changes in the number of processes of type II and type III 
astrocytes in the dentate gyrus at 1 hour after a test of fear 
conditioning. Meanwhile, the intersections of type III 
astrocytes were not changed in the auditory cortex (Fig.1-3b). 
In this area, the numbers of type I and II astrocytes were much 
smaller than type III astrocytes, unlike in the dentate gyrus. 
 
3. Protein levels of GFAP, PSD-95, EAAT2 and Cx43 were 
altered in the hippocampus by contextual fear conditioning 
Next, I analyzed the protein levels of GFAP, postsynaptic 
density protein 95 (PSD-95), EAAT1, EAAT2 and Cx43 to 
investigate the molecular changes accompanied by 
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morphological changes in astrocytes induced by hippocampal 
contextual memory formation. I found that the protein levels 
of GFAP, a reactive astrocyte marker, were significantly 
decreased in the hippocampus of the test group at 1 hour after 
the conditioning test compared with the control group (Fig. 1-
4b). 
   Long-term memory induction strengthened synaptic 
connectivity of hippocampal neurons. The protein levels of 
PSD-95, a major post-synaptic scaffolding protein, was 
evaluated in the hippocampus after fear conditioning was 
performed [120]. PSD-95 protein level was significantly 
increased at 1 hour and at 24 hours (Fig 1-4b). 
   The protein level of EAAT2, glutamate transporter which 
is specifically expressed in astrocytes [121, 122], was 
increased at 1 hour and 24 hour (Fig. 1-5b), while EAAT1 did 
not show any changes (data not shown). Cx43 is a major gap 
junction protein that connects astrocytes. Recently, it has 
been reported that Cx43 not only serves as a gap junction 
protein but also exerts functions as a hemichannel to affect 
neuron functions during inflammation [123]. The protein level 
of Cx43 was not significantly increased at 1 hour in the test 
group. But it was increased at 24 hour (Fig. 1-5b). Taken 
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together, these data suggest that during the formation of 
contextual fear memory formation, astrocytes change 
dynamically with reduced protein levels of GFAP and 
increased levels of EAAT2 and Cx43 proteins. This appears to 
be a different status of astrocytes from the typical resting or 
reactive states. 
 
4. LAA injection into the dentate gyrus inhibited the 
contextual fear memory expression after the fear conditioning 
L-α-aminoadipate (LAA), a glutamate analogue, has been 
generally accepted to exert astrocyte-specific toxicity, 
although the exact mechanism is not fully elucidated [124-
126].  20 μg of LAA was injected into the dentate gyrus via 
stereotaxic surgery. Forty-eight hours after the injection, I 
evaluated the protein levels of GFAP and NeuN via Western 
blotting and immunohistochemistry (Fig. 1-6a, b). The 
protein level of GFAP was significantly decreased by LAA 
injection by approximately 70 %, while that of NeuN was not 
significantly altered. This result was also confirmed with 
immunohistochemistry (Fig. 1-6c). These data indicate that 
LAA injection into the dentate gyrus specifically reduced the 
numbers of astrocytes but not of neurons.  
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 I performed contextual fear conditioning test with the 
control and LAA-injected mice groups. The timetable for LAA 
injection and contextual conditioning is shown in Fig. 1-7a. 
Motor function did not show a significant difference between 
the control and LAA-injected mice group during fear 
conditioning (Fig. 1-7b). There was no significant difference 
in the freezing time between the control and LAA-injected 
group during fear conditioning (Fig. 1-8a). However, in the 
test, 24 hours after fear conditioning, the LAA group showed 
significantly decreased time freezing compared to the 

















Figure 1-1. Fvb/n mice were trained to contextual fear 
conditioning  
(a) Illustration of the scheme for contextual fear conditioning 
test (b) At training day, mice displayed the increased freezing 
time at 1st and 2nd electric shocks (1/2), the 2nd and 3rd  (2/3) 
and after the 3rd electric shocks (3/E) 1/2, 2/3 and 3/E, (17.43 
± 7.86 %, 32,95 ± 2.88 % and 55.83 ± 5.72 %, N=10), At 
teat day, the test group exhibited the increased freezing 
(71.786 ± 3.84 %, N=10, ***p<0.001), compared to the 
control group (4.817 ± 0.447 %). The data are displayed as 










Figure 1-2. Morphological changes in astrocytes were 
detected in the hippocampal dentate gyrus   
 (a) Morphological analysis of type II and type III astrocytes 
by sholl analysis., Concentric circles are spaced at 10μm). (b) 
The number of intersections between each circle and 
processes of type II astrocytes in dentate gyrus from control, 
1 hour and 24 hour groups at 15μm (control: 9.216 ± 1.023, 
1 hour: 11.988 ± 0.737 *p<0.05). At 20μm (control; 3.056 ± 
0.285, 1 hour; 7.106 ± 0,798 ***p<0.001), 24 hour; 5.391 ± 
0.569, *p<0.05). At 25μm (control: 0.929 ± 0.0213, 1h; 2.217 
± 0.420, **p<0.01)) (control, N=9, 1 hour, N=10, 24 hour, 
N=8). (C) the number of intersections between each circle and 
processes of type III astrocyte in the dentate gyrus from 
control, 1 hour and 24 hour group, at 15 μm (control; 13.036 
± 0.669, 1 hour; 15.618 ± 0.473, **p<0.01). At 15 μm 
(control; 10.083 ± 0.821, 1 hour 13.543 ± 0.998, *p<0.05). At 
20 μm (control, 4.132 ± 0.704, 1 hour; 7.906 ± 0.908, 
*p<0.05). At 25 μm (control; 1.184 ± 0.248, 1 hour; 2.905 ± 
0.476, *p<0.05). At 30 μm (control; 0.207 ± 0.081, 1 hour; 
0.767 ± 0.199, *p<0.05) (control, N=10, 1 hour, N=12, 24 hour, 














Figure 1-3. Morphological changes in astrocytes were 
examined in the auditory cortex  
(A) Morphological analysis of type III astrocytes by a Sholl 
analysis. (Immunofluorescence for GFAP, gradation from red 
to blue; depth of Z-projection is 0-30 μm, Concentric circles 
are spaced at 10 μm). (B) Number of intersections between 
each circle and processes of type III astrocytes in auditory 
cortex from control, 1 hour and 24 hour groups at 10μm 
(control; 21.133 ± 1.171, 1 hour; 19.955 ± 1.150, 24 hour; 
18.438 ± 0.953). At 15μm (control; 27.000 ± 1.009, 1 hour; 
28.273 ± 1.269, 24 hour; 24.813 ± 1.461). At 20μm (control; 
25.800 ± 1.509, 1 hour; 27.682 ± 1.641, 24 hour; 22.375 ± 
1.695). At 25μm (control; 18.067 ± 2.233, 1 hour; 18.182 ± 
1.411, 24 hour; 14.813 ± 1.844). At 30μm (control; 7.533 ± 
1.077, 1 hour; 9.455 ± 1.314, 24 hour; 6.063 ± 1.349) 
(control, N=7, 1 hour, N=8, 24 hour, N=7). The data are 
















Figure 1-4. Protein expression of GFAP and PSD-95 were 
altered in the hippocampus by contextual fear conditioning  
(A) Representative immunoblots for GFAP, PSD-95 and 
GAPDH for control, 1 hour and 24 hour groups. (B) 
Densitometric analysis of immunoblots for GFAP (control, 
1.000 ± 0.8198, 1 hour, 0.7173 ± 0.07201, *p<0.05, N=9) 
and PSD95 (control; 1.000 ± 0.193, 1 hour; 2.800 ± 0.352, 
**p<0.01, 24 hour; 2.535 ± 0.388, *p<0.05, N=9). The data 














Figure 1-5. Protein expression of EAAT2 and CX43 were 
altered in the hippocampus by contextual fear conditioning  
(a) Immunoblots for EAAT2, Cx43 and GAPDH for control, 1 
hour and 24 hour groups. (b) Densitometric analysis of 
immunoblots for EAAT2 (control; 1.000 ± 0.121, 1 hour; 
2.238 ± 0.386, *p <0.05, 24 h; 2.070 ± 0.377, *p<0.05, N=6) 
and Cx43 (control; 1.000 ± 0.233, 1 hour; 1.280 ± 0.146, 24 
hour; 1.759 ± 0.245, *p<0.05). The data are displayed as the 






























Figure 1-6. LAA injection in the dentate gyrus reduced the 
population of astrocytes but not that of neurons   
(a) Representative immunoblots for GFAP, NeuN and GAPDH 
in hippocampus for the control and LAA groups. (b) 
Densitometric analysis of immunoblots for GFAP (control; 
1.000 ± 0.11, LAA; 0.307 ± 0.058, **p<0.01, N=5) and 
NeuN (control; 1.000 ± 0.011, LAA; 1.285 ± 0.021, N=5). (c) 
Immunofluorescence for GFAP, NeuN and DAPI in 
hippocampus for the control and LAA groups. The data are 














Figure 1-7. LAA injection did not affect the motor function  
(a) Schedule for contextual fear conditioning with control and 
LAA- injected mice. (b) The total distance was examined for 
both control and LAA group with auto-tracking system in 
Ethovision. (control; 1711.334 ± 90.161, LAA; 1600.309 ± 
80.135, N=10). The velocity was calculated for the control and 
LAA groups with the auto-tracking system in Ethovision 
(control; 32.997 ± 1.281, LAA; 33.680 ± 2.735, N=10). The 











Figure 1-8. LAA injection in the dentate gyrus reduced the 
expression of fear memory after contextual fear conditioning  
(a) During fear conditioning, the control and LAA groups 
displayed increased time freezing at 1st and 2nd electric shocks 
(1/2), the 2nd and 3rd (2/3) and after the 3rd electric shocks (3/E) 
(control; (1/2) 25.54 ± 5.888%, (2/3) 29.51 ± 7.649%, (3/E) 
74.66 ± 6.732%, LAA; (1/2) 34.00 ± 9.110%, (2/3) 47.00 ± 
7.824%, (3/E) 83.63 ± 3.698%, N=10). During fear expression, 
after 24 hours the electric shock, the control and LAA groups 
showed increased time freezing (control; 63.169 % ± 7.911%, 
LAA; 14.784 % ± 4.610 %, ***p<0.001, N=10). The data are 





In the present study, I investigated the morphological and 
molecular changes in astrocytes based on the hypothesis that 
these changes are accompanied by long-term memory 
induction in the dentate gyrus of the hippocampus. Fvb/n mice 
were exposed to contextual fear conditioning test, and 
checked for morphological and molecular changes in 
astrocytes. I found that 1 hour after fear conditioning, type II 
and type III astrocytes exhibit a unique status with an 
increased number of processes and decreased protein level of 
GFAP which differ from the typical resting or reactive states. 
The reactive state of astrocyte is known to show increased 
GFAP expression level [127]. However, my results showed 
that hippocampus-dependent contextual memory induced 
increased intersections of type II and type III astrocytes but 
decreased GFAP protein levels were observed. In addition, I 
also found that the protein levels of EAAT2 and Cx43 were 
increased. Previously, it has been reported that physical 
exercise improved learning and memory capability and induced 
an increase in the number of astrocyte processes [128]. Taken 
together, these results suggest that an altered astrocytic state 
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is necessary to induce the learning and memory process. In a 
recent MRI study in humans and rodents, Sagi et al showed that 
the complexity of the hippocampal dentate gyrus was 
increased after acquisition of spatial memory [129]. In 
addition, the intensity of GFAP protein was increased in the 
hippocampus in an immunofluorescence study.         
In my study, I used confocal laser scanning microscopy. A live 
imaging system such as two-photon confocal laser scanning 
microscopy is needed to observe dynamic morphological 
changes of hippocampal astrocytes during contextual memory 
formation.  
   The increased number of astrocyte processes suggest an 
increase in the interaction with neurons, i.e. number of 
tripartite synapses. In addition, other studies have 
demonstrated that improved learning and memory capability is 
accompanied by the increased number of astrocyte processes. 
Further study with high resolution, such as at the electron 
microscope level is needed to image invasion into tripartite 
synapse structure. Additionally, the mechanism between the 
increased number of astrocyte processes and decreased 
expression of GFAP observed in the current study remains 
unclear.  
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These morphological and molecular changes during memory 
induction in astrocytes might involve increased action 
potentials on neurons. Neurons with action potentials increase 
the secretion of neurotransmitters, especially glutamate from 
presynaptic terminals [130]. Glutamate released from 
presynaptic terminals binds to  glutamate receptors and is 
uptaken via EAATs in astrocytes [131]. These receptors bind 
glutamate to promote the intracellular calcium level in 
astrocytes [132]. The increased calcium levels promote 
functional changes in astrocytes as changes in gene expression 
and gliotransmitter release. This phenomenon is one of the 
mechanisms for the molecular changes in the expression of 
EAAT2 and Cx43 on astrocytes. The increased EAAT2 protein 
expression on astrocytes might reduce excitotoxicity at 
synapses. The increased Cx43 protein expression on 
astrocytes might be responsible for the spread of signals 
around astrocytes to harmonize such function as glutamate 
uptake or gliotransmitter release. LAA is well known to exert 
astrocyte-specific toxicity. A previous report showed that 20
μg of LAA was injected into the dentate gyrus to reduce the 
number of astrocytes in this area [133]. I confirmed that LAA-
injected mice group showed a significant decreased freezing 
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time in the test day of contextual fear conditioning test. The 
reason of cognitive impairment of LAA injected mice are 
supposed the absence of gliotransmitter as D-serine from 
astrocytes. The D-serine has the important function to 
modulate LTP in hippocampal neurons. The one of main 
reason of cognitive impairment are suggested the neuronal 
dysfunction as the alteration of LTP [134-136]. These data 
suggest that the presence of astrocyte is critically required for 
the formation of long-term memory. The results shown in 
Chapter 1 and the hypothesis for the study of Chapter 2 are 
summarized in Graphical Summary as below.  
Collectively, the increased numbers of astrocyte processes and 
the decreased GFAP expression level in the dentate gyrus are 
correlated with hippocampal dependent long-term memory 
induction. These morphological and biological changes, i.e., 
the altered protein level of GFAP was returned to the control 
level at 24 hour. The characteristics of astrocytes observed in 
the current study are different from the resting or reactive 
states of astrocytes. Thus, a dynamic change from the memory 
induction state astrocyte is correlated with the induction of 
long-term memory. 
These results show that hippocampus-dependent contextual 
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fear memory process results in the changes in the status of 
astrocytes towards a novel status different from typical resting 
or reactive states. These morphological and molecular 
changes may be in line with functional changes. In Chapter 2, 
I investigated the relationship between reactive astrocytes 
and cognitive impairments using an AD animal model, 5XFAD 
mice. Morphological and molecular changes were investigated 
in astrocytes after memory induction by a hippocampus-
dependent contextual fear conditioning test. In addition, the 
interaction between neurons and astrocytes at synapses was 
also evaluated.  
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Graphical Summary: Chapter 1 
The dynamics of molecular and morphological change in 














Reactive astrocytes often observed in AD brains are thought 
to lose neuroprotective functions of astrocytes in resting state 
including uptake and degradation of Aβ[137]. Resulting 
accumulated Aβ in turn stimulates to induce pro-
inflammatory factors in glial cells [138]. Astrocytes are 
reported to be activated into the reactive state via 
JAK/STAT3, NF-κB, MAPK and NFAT pathways [139].  
Reactive astrocytes show functional and morphological 
changes as a result of diversity of brain insults. The 
characteristics of reactive astrocytes is represented by 
increased gene expression of a number of structural proteins, 
such as GFAP and vimentin. Also, reactive astrocytes show the 
morphological changes, such as hypertrophy of the cell soma 
and increased the number of processes. Proliferation of 
astrocytes is especially important in the formation of scar 
formation around tissue lesions [7, 140-142].  
However, complicated mechanisms underlying the transition 
from the resting state to the reactive state of astrocyte in 
neurodegenerative diseases largely remain unclear. 
Additionally, how reactive astrocytes affect cognitive function 
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apart from their neurotoxic effects remains still unclear. 
I investigated which pathways are involved in the activation 
of astrocytes into reactive astrocytes in the context of AD. 
Oligomeric Aβ (oAβ) was treated to primary cultured 
astrocytes. oAβ-treated astrocytes was activated into 
reactive state via phosphorylated signal transducer and 
activator of transcription 3 (p-STAT3). The inhibition of 
STAT3 to oAβ-treated astrocytes attenuated the activation of 
astrocytes into reactive astrocytes. In addition, systemic 
administration of Sttatic, an inhibitor of STAT 3, for 14 days 
attenuated the impairment of cognitive function in 6-month-
old 5XFAD mice as assessed by contextual fear conditioning 
test.  
 54 
MATERIALS AND METHODS 
 
1. Reagents and antibodies 
  Protein isolation with RIPA lysis buffer was purchased from 
Elpis biotech (#EBA-1149, Daejeon, Korea) and Pierce™ BCA 
Protein Assay Kit was purchased from Thermo (#23227, MA, 
USA). Anti-GFAP, rabbit polyclonal antibody was purchased 
from DAKO (#Z0334, CA, USA). Anti-NeuN rabbit monoclonal 
antibody, synaptophysin mouse monoclonal antibody were 
purchased from Millipore (#3838 and #MAB329, MA, USA). 
Anti-PSD-95, mouse monoclonal antibody, anti-rabbit, goat 
polyclonal tagged Alexa Fluor 488, anti-mouse, goat 
polyclonal tagged Alexa Fluor 555 and 4’. 6-diamidino-2-
phenylinodole (DAPI) were purchased from ThermoFisher 
(#MA1-046, #A11034, #A11012, #A21426 and #D3571, MA, 
USA). Anti-GAPDH, rabbit polyclonal antibody was purchased 
from AbFrontier (#LF-PA0018, Seoul, Korea). Rabbit 
polyclonal antibody was purchased from WAKO (#016-20001, 
Osaka, Japan). Anti-mouse, sheep polyclonal horseradish 
peroxidase (HRP) tagged antibody was purchased from Abcam 
(#ab26116, #ab26113 and #ab6808, EA, UK). Anti-p-STAT3 
(Tyr 705), STAT3, p-p44/42, p44/42 rabbit polyclonal 
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antibody was purchased from Cell signaling (#9145, #12640, 
#4377 and #4695 MA, USA). Anti-NF-κB mouse monoclonal, 
Anti-BACE1 rabbit polyclonal antibodies were purchased from 
Santa Cruz (#sc-7151, Taxas, USA). Anti-β-amyloid, 1-16 
mouse monoclonal antibody was purchased from 
Biolegend(#803001, San Diego, USA). Anti-Aβ neutralizing 
antibody was purchased from BPS Bioscience (#71223, San 
Diego, USA). 
 
2. Experimental animals 
All of the experimental procedures were approved by the 
Animal Care Committee of Seoul National University 
(Approval number: SNUIBC-171011-2). Transgenic mice 
with 5XFAD mutations were purchased from Jackson 
Laboratories (strain: B6SJL-Tg [APP Sw, Fl, Lon, PS1, M146L, 
L286V] 6799Vas/J) and maintained by crossing hemizygous 
transgenic mice with B6SJL F1 mice. Six-month-old male 
mice were used for the experiments. The mice were housed in 
four or five per cage with a 12-hour light/dark cycle and ad 




3. Primary astrocyte culture 
The primary astrocyte culture was described previously [143]. 
Briefly, primary mixed glial cultures were prepared from 
postnatal day 1 (P1) C57B/L6 mice. The cortex was 
dissociated and it was incubated with 0.25% trypsin in 37°C 
water bath for 20 minutes. The incubated cortex filtered with 
a cell strainer. The mixed glia cells was grown in Dulbecco’s 
modified Eagle’s medium (DMEM), supplemented with 10% 
(vol/vol) heat-inactivated FBS and penicillin (10 units/ml) 
and streptomycin (10 mg/ml) in a humidified cell incubator 
(Binder, Germany) at 37°C under a 5% CO2 atmosphere. When 
the mixed glia filled 80% of the T75 plate at DIV-14, 
astrocyte and microglia were separated via a 250 rpm shaking 
incubator at 37°C for overnight. Microglia were detached 
from the plate after shaking isolation. The astrocytes were 
detached with incubation 0.25% trypsin-EDTA at 37°C under 
a 5% CO2 atmosphere for 5 minutes. Next the astrocytes 
seeded onto poly-L-lysine coated plates for the experiment.    
 
4. Oral administration of Stattic   
Sttatic (25 mg/kg per day) dissolved in drinking water was 
freely administrated to 6-month-old WT and 5XFAD mice.  
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Animals were divided into 4 groups consisting of 9–10 mice. 
WT-vehicle and 5XFAD vehicle, which drank only water, were 
used as control groups. WT-stattic and 5XFAD-stattic, which 
drank stattic included water, were used as administration 
groups. To examine toxicity of Sttatic, water, food intake and 
body weight was evaluated at 2 weeks. After all groups of mice 
were scarified the brain weight was measured. Behavior tests 
were performed after 15 days’ treatment.   
 
5. Oligomeric Aβ1-42 preparation  
oAβ oligomerization was prepared previously described [144, 
145]. Synthetic human Aβ1-42 peptide (American Peptide, 
Sunnyvale, CA, USA) was dissolved to 1 mM in 100% 
hexafluoro isopropanol (HFIP, Sigma Chemical Company, MO, 
USA). The solution was evaporated to filmization Aβ in a 
Speed Vac (SPD2010, Thermo Savant, NY, USA) for 2 hours. 
The resulting peptide film was stored at −20 °C or 
immediately resuspended in dimethyl sulfoxide (DMSO, Sigma 
Chemical Company) to produce a 1 mM solution. Then, this 
solution was diluted to 100 μM in phenol red-free Ham’s F-
12 medium (Life Technology, NY, USA) and incubated for 12 
hours at 4°C.  
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6. Contextual fear conditioning test 
Contextual fear conditioning test was performed as previously 
described [7]. Briefly, all experimental animals had been 
handling for 5 days before preforming contextual fear 
conditioning test. Prior to training, all 4 groups mice were 
positioned into the chamber (13 × 13 × 25 cm) for 10 min to 
habituation. On the second day, each mouse was positioned in 
the conditioning chamber for 3 min and acquired three 
repetitions of a foot-shock (0.7 mA, 2 sec) at 1 min intertrial 
intervals during the training day. On the next day, the trained 
mice were positioned in the same chamber, and the freezing 
behavior was measured over periods of 3 min. The freezing 
behavior was defined as immobility except for respiratory 
movements. The latency of total freezing time was analyzed as 
a percentage in the test period. The all groups mice were 
sacrificed after the test day. 
 
7. T-maze test 
T-maze test was performed as previously described [146]. 
Briefly, prior to training, all four groups mice were placed the 
room with deem light to habituation for 1 hour. The testing 
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mice was positioned at the starting zone. After the mice 
choose one way, the way was blocked and the mice stay for 30 
sec. During clean the T-maze with 30% EtOH, the mice stayed 
in the home cage for 1 min and return into the starting zone. 
If the mice chose the other way, it will get 1 point. If the mice 
chose the same way, it will get 0 point. This trial performed 
the next day.   
 
8. Western blotting 
Western blotting analysis was described previously [146]. 
Briefly, the mice were anesthetized with Zoletil (12.5 mg/kg) 
and Rompun mix (17.5 mg/kg) and the dissected brain tissues 
were stored at -80°C before protein lysis. Hippocampi were 
homogenized with RIPA mix including as protease inhibitor, 
Sodium fluoride, phenylmethylsulfonyl fluoride and sodium 
orthovanadate. The primary antibodies were applied in the 
following concentrations: anti-GFAP (rabbit, 1: 5,000), anti-
NeuN (rabbit, 1: 1,000), anti-p-STAT3 (rabbit, 1:1,000), 
anti-STAT3 (rabbit, 1:1,000), anti-p-p44/42 (rabbit, 
1:1,000), anti-p44/42 (rabbit, 1:1,000), anti-p-p65 (rabbit, 
1:1,000), anti-p65 (rabbit, 1:1,000), anti-PSD95 (mouse, 
1:2,000), anti-synaptophysin (mouse, 1:2,000), anti-Aβ 
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(mouse 1:1,000), anti-BACE1 (rabbit, 1:1,000), anti-GAPDH 
(rabbit, 1:10,000). Secondary antibodies were conjugated with 
HRP (1: 2,000). The HRP signals were visualized using an 
enhanced chemiluminescent substrate. 
 
9. Immunofluorescence   
The protocol was previously described in the paper by Choi et 
al [7]. The brains were perfused with heparin dissolved in PBS 
(pH 7.2) for 5 min were fixed with 4 % paraformaldehyde for 
24 hours. The fixed brains were transferred into 30 % sucrose 
solution for 48 hours. The brain tissue was sectioned into 30 
μm thick slices with a cryotome with the chamber at -20°C 
and the bar temperature at -25°C.  
For GFAP and NeuN staining, the brain sections were heated 
in a 95°C water bath for 30 min with 10 mM citrate acid (pH 
6.0) for antigen retrieval. The sections were blocked with 2 % 
BSA and 0.3 % Triton X-100 in PBS for 1 hour. Primary 
antibodies GFAP (1:1,000) and NeuN (1:500) were applied 
overnight at 4°C. Secondary antibodies, anti-rabbit-488 
(1:200) and anti-mouse-555 (1:200) were applied for 2 hours 
at room temperature. For p-STAT3 and GFAP staining, the 
brain sections were permeabilized with MetOH in -20°C for 
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20 min. The permeabilized brain sections 
heated in 85°C water bath for 10 min with 10 mM sodium 
citrate (pH 8.5) for antigen retrieval. The sections were 
blocked with 2 % BSA and 0.3 % Triton X-100 in PBS for 1 
hour. Primary antibodies p-STAT3 (1:200) and GFAP (1:1,000) 
were applied overnight at 4°C. Secondary antibodies, anti-
rabbit-488 (1:200) and anti-goat-555 (1:200) The stained 
brain tissue samples were imaged with confocal microscopy 
using LSM 510 (Carl Zeiss, Germany) or A1 (Nikon, Japan).   
 
10. Statistical analysis 
Data are expressed as the mean ± SEM (means ± standard 
error of the mean). One-way ANOVA followed by Tuckey post 
hoc analysis or Student ’ s t-test (SPSS, IL, USA) was 
performed to determine statistical significance. The results 















1. Six-month-old 5XFAD mice showed the increase in the 
reactive astrocytes and the impairments in hippocampal 
dependent long-term memory formation  
First, in order to determine which cell type is altered in the 
hippocampi of 6-month-old WT and 5XFAD mice, I evaluated 
the protein expression of GFAP and NeuN. 5XFAD mice shown 
an increase in reactive astrocytes as compared to the WT group 
as assessed by the protein expression of GFAP. However, the 
protein level of NeuN was not different between WT and 
5XFAD mice (Fig. 2-1a, b). Next, I stained the brain slices of 
6-month-old 5XFAD mice and age matched WT mice with 
GFAP, NeuN and DAPI and assessed immunofluorescence. 
Consistently, GFAP immunoreactivity was higher in 5XFAD 
mice than in WT mice, whereas NeuN immunoreactivity was 
not different between the WT and 5XFAD groups (Fig. 2-1c). 
Even in the absence of neuronal loss in the hippocampus, 
neuronal function can be altered by the degradation of synaptic 
proteins. Thus, I evaluated the protein levels of 
synaptophysin, presynaptic maker and PSD-95, postsynaptic 
marker. respectively, to determine whether the pre- or 
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postsynaptic components are altered and damaged in the 
hippocampus of 6-month-old WT and 5XFAD mice. Altered 
protein expression was not observed for both synaptic marker 
proteins expression such as PSD-95 and synaptophysin in 6-
month-old 5XFAD mice (Fig. 2-2a, b).  
To test hippocampus-dependent long-term spatial memory, 
contextual fear conditioning test was performed with 6-
month-old WT and 5XFAD mice. The time schedule of 
contextual fear conditioning test is shown (Fig. 2-3a).  First, 
I analyzed the time of freezing behavior at intervals between 
every electric shock on the training day. WT group mice 
showed a significant increase the freezing time throughout the 
training session. The 5XFAD mice group also showed a 
significant increase the freezing time throughout the session 
(Fig. 3b). These results indicate that neither both groups 
showed not altered short-term memory formation. But both 
groups were well trained via the contextual fear conditioning 
test training procedure. The freezing behavior of the WT and 
5XFAD mice were analyzed on the test day. 5XFAD mice 
displayed significantly decreased the freezing time than WT 
mice (Fig. 2-3c). These results showed that 6-month-old 
5XFAD mice increased in reactive astrocytes as assessed by 
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the protein expression of GFAP, and impaired hippocampal-
dependent long-term spatial memory. However, significant 
differences in neuronal and synaptic marker proteins were not 
observed.  
  
2. Astrocytes were activated via STAT3 phosphorylation in 
vitro and in vivo AD model  
Astrocytes are activated into reactive state by cytokines, 
chemokines and aggregated proteins via the JAK/STAT3, NF-
κB, MAPK and NFAT pathways [139]. Primary cultured 
astrocytes treatment with 250 nM oAβfor 24 hours, I analyzed 
the protein expression of GFAP by western blot. The protein 
expression of GFAP was significantly increased in oAβ-
treated group (Fig. 2-4a and b). Next, I performed western blot 
to determined which pathways are activated by oAβ 
treatment in primary cultured astrocytes (Fig. 2-5a). The 
protein expression of p-STAT3 and STAT3 were significantly 
increased in oAβ-treated primary cultured astrocytes. 
However, p-p65, p65, p-ERK and ERK protein expression 
were not altered (Fig. 2-5b). The protein expression of p-
STAT3 and total STAT3 was significantly higher in the 
hippocampus of 6- month-old 5XFAD mice than in that of WT 
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mice, while the protein expression of p-p65, p65, p-ERK and 
ERK was not altered (Fig. 2-6a and b). These results indicated 
that the STAT3 pathway was activated in the hippocampus of 
6-minth-old 5XFAD mice. Then, immunofluorescent 
experiment was performed to investigate which cell types 
display p-STAT3 in the brains. It was found that p-STAT3 
fluorescent signals were colocalized over approximately 80% 
in the nucleus of astrocytes statined with GFAP in the 
hippocampus of 5XFAD mice (Fig. 2-7a and b). The p-STAT3 
signal was rarely colocalized with Iba-1 and NeuN in the 
hippocampus of 6-month-old 5XFAD mice (Fig. 2-7c). These 
results indicate that astrocytes are activated into a reactive 
state via STAT3 phosphorylation in 6-month-old 5XFAD 
mice. 
 
3. Oral administration of Stattic, an inhibitor of STAT3, 
attenuated the cognitive impairments in 5XFAD mice 
STAT3 inhibitors such as Stattic, S31-201 and 
crypotanshinone have been developed and used for breast and 
prostate cancer therapy [147, 148]. Primary cultured 
astrocytes were treated time-dependently with 1μM Stattic 
from 1 hour to 12 hours (Fig. 2-8a). The p-STAT3 protein 
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expression was significantly decreased than in those treated 
with vehicle in Stattic-treated primary cultured astrocytes 
from 1 hour to 6 hours (Fig. 2-8b). The STAT3 protein 
expression was not altered from 1 hour to 12 hours. The p-
STAT3 and STAT3 ratio was also significantly decreased in 
Stattic-treated primary cultured astrocytes form 1 hour to 6 
hours (Fig. 2-8b). In addition, the GFAP protein expression 
was significantly decreased in Stattic-treated primary 
cultured astrocytes from 3 hours to 6 hours (Fig. 2-8b).  
The time schedule of administration and behavior tests are 
shown (Fig. 2-9a). After sacrificed experiment mice, the 
hippocampi were removed and STAT3 pathway activated in 
astrocytes was analyzed. The hippocampi of vehicle-treated 
5XFAD mice (5XFAD-V) showed significantly increased 
expression of p-STAT3 than those of vehicle-treated WT 
mice (WT-V). Stattic significantly reduced the 
phosphorylation of STAT3 in Stattic-treated 5XFAD mice 
(5XFAD-S), although the p-STAT3 levels were still 
increased than those in WT-V (Fig. 2-9b). The STAT 
expression was not changed in WT-S, 5XFAD-V and 5XFAD-
S (Fig. 2-9b). The protein expression of GFAP was found to 
be significantly increased in the hippocampi of 5XFAD-V 
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mice than in those of WT-V mice. Stattic administration 
significantly reduced the protein expression of GFAP (Fig. 2-
9b). These results suggest that the systemic administration of 
Stattic restored the activation of astrocyte in the hippocampus 
via the STAT3 pathway. 
I confirmed whether Stattic administration exerts 
detrimental effects in experimental animals. Body weight and 
brain weight were not significantly different between the 
vehicle- and Stattic-treated groups over 15 days (Fig. 2-10a). 
Next, I performed the T-maze test to determine the working 
memory. The percentage of alternation was significantly 
decreased in 5XFAD-V than in the WT-V. However, Stattic 
treatment significantly increased the percentage of 
alternation in 5XFAD-S compared with 5XFAD-V (Fig. 2-11a). 
Additionally, I performed the contextual fear conditioning test 
to determine hippocampal-dependent long-term spatial 
memory. On the habituation day, all groups displayed similar 
the time of freezing behavior less than 5% (Fig. 2-11b). On 
the training day, all groups displayed a significant increase the 
time of freezing behavior after each electric shock, but this 
increase the freezing time did not differ significantly among 
the groups (Fig. 2-11b). On the test day, the time of freezing 
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behavior was significantly decreased in the 5XFAD-V group 
than in the WT-V group. However, 5XFAD-S mice displayed 
a significantly increased the time of freezing behavior than 
the 5XFAD-V mice (Fig. 2-11b).  
These results suggest that administration of Stattic show the 
effect of Stattic on restoring the working and long-term 
spatial memory via inhibition of the STAT3 pathway in 
5XFAD mice. 
 
4. Oral administration of Stattic restored the activation of 
astrocytes in 5XFAD mice 
Here, I analyzed the activation state of astrocytes and p-
STAT3 expression after the systemic administration of Stattic 
in mice. I performed immunofluorescence analysis to indicate 
which cell types expression of p-STAT3 protein and the 
activation of astrocyte were changed by administration of 
Stattic in 5XFAD mice (Fig. 2-12a). In the hippocampus of 
both WT-V and WT-S group mice, the expression of p-STAT3 
protein was too low to detect. The region of intensity (ROI) of 
p-STAT3 was significantly decreased in 5XFAD-S mice than 
in 5XFAD-V mice (Fig. 2-12b). Next, I analyzed the 
colocalization of p-STAT3 and GFAP after the administration 
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of Stattic in 5XFAD mice. The colocalization was significantly 
decreased in 5XFAD-S mice than in 5XFAD-V mice (Fig. 2-
12b). GFAP immunoreactivity was significantly increased in 
the 5XFAD-V group than in the WT-V group. The ROI of 
GFAP was significantly decreased in 5XFAD-S mice than in 
5XFAD-V mice (Fig. 2-12b). In addition, I quantified the 
characteristic features of reactive astrocytes, such as the 
number of processes and cell volume. The Z-stack image of 
GFAP immunofluorescence with brain slice were 3D 
reconstructed. The number of intersections were analyzed 
with sholl anlysis. The number of intersections was 
significantly increased in 5XFAD-V mice and significantly 
decreased in 5XFAD-S (Fig. 2-13a, b). The Z-stack image of 
GFAP immunofluorescence with brain slice were processed 
with IMARIS software. The volume of astrocyte was 
significantly increased in 5XFAD-V mice and significantly 
decreased in 5XFAD-S mice (Fig. 2-14a, b). These results 
suggest that the systemic administration of Stattic has the 
potential to restore the STAT3 phosphorylation in astrocytes, 




5. Oral administration of Stattic reversed the decrease in the 
number of tripartite synapses in the hippocampus of 5XFAD 
mice 
Next, the interaction between PSD-95-positive dendritic 
spines and GFAP-positive astrocytic processes was analyzed 
to identify tripartite synapses. Brain slices of contextual fear 
conditioning-trained WT-V, WT-S, 5XFAD-V and 5XFAD-S 
were stained with anti-PSD-95 and anti-GFAP antibodies to 
identify the number of tripartite synapses (Figure 2-15a). 
These stained brain slices were imaged via Z-stack confocal 
microscopy. The 3-D reconstructed images were sectioned by 
the X-Z axis and the interaction of the PSD-95 and GFAP 
signals in the cross-sections of the hippocampal dentate gyrus 
images was measured (Figure 2-15b). Intriguingly, the PSD-
95 and GFAP interaction was significantly lower in the 
5XFAD-V mice than in the WT-V and WT-S mice and 
recovered to WT-V levels with Stattic treatment (Figure 2-
15b). These results indicated that the administration of 
Stattic has the potential to restore the number of tripartite 
synapses and cognitive function in AD. 
 
6. Oral administration of Stattic reduced the protein level of 
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Aβin 5XFAD mice 
Protein level of Aβ and the number of senile plaques was 
evaluated after systemic administration of Stattic in 6-
month-old 5XFAD mice. Thioflavin-S staining was performed 
to determine the number of senile plaques after Stattic 
administration in 5XFAD mice (Fig. 2-16a). The number of 
senile plaques was significantly higher in 5XFAD-V mice than 
in WT-V mice and found to be significantly decreased in 
5XFAD-S (Fig. 2-16b). Next, the protein level of Aβwas 
analyzed after systemic administration of Stattic in 5XFAD 
mice by western blotting. The protein level of Aβwas 
significantly decreased in 5XFAD-S mice than in 5XFAD-V 
mice (Fig. 2-17a, b). The reduction in Aβmay be caused by 
deceased production or increased clearance. To determine 
which mechanisms are involved in the reduced protein level 
of Aβ, the protein expression of BACE1 was investigated after 
systemic administration of Stattic in 6-month-old 5XFAD 
mice. The protein level of BACE1 was significantly decreased 
in 5XFAD-S mice (Fig. 2-18a, b). These results suggest that 
the systemic administration of Stattic has a potential to reduce 


































Figure 2-1. Astrocytes were activated without neuronal loss 
in the hippocampus of 6-month-old 5XFAD mice  
(a) Representative immunoblots for neuronal marker NeuN and 
astrocyte marker GFAP from the WT (N = 7) and 5XFAD (N = 
9) hippocampus. (b) Densitometric analysis of immunoblots 
for NeuN (WT: 1.00 ± 0.024, N=7, 5XFAD: 1.024 ± 0.149, 
N=9) and GFAP (WT: 1.00 ± 0.159, N=7, 5XFAD: 3.476 ± 
0.424, N=9, **p<0.01). (c) Immunofluorescence for NeuN and 
GFAP in the hippocampal dentate gyrus of both WT and 5XFAD 

















Figure 2-2. Synaptic proteins were not altered in the 
hippocampus of 6-month-old 5XFAD mice  
(a) Representative immunoblots for postsynaptic marker. 
PSD-95 and presynaptic marker, synaptophysin from the WT 
and 5XFAD hippocampus. (N = 6) (b) Densitometric analysis 
of immunoblots for PSD-95 (WT: 1.00 ± 0.052, N=6, 5XFAD: 
0.933 ± 0.159, N=6) and synaptophysin (WT: 1.00 ± 0.054, 
N=6, 5XFAD: 0.835 ± 0.053, N=6). The data are displayed as 


















Figure 2-3. Cognitive function was impaired when tested with 
contextual fear conditioning test in 6-month-old 5XFAD mice  
(a) A time schedule for the contextual fear conditioning test 
is shown. (b) Quantification of freezing behavior for fear 
conditioning (WT: 10.09 ± 2.42 %, 16.23 ± 3.61 % and 23.46 
± 3.16 %, N=10, *p<0.05, 5XFAD: 13.80 ± 2.83 %, 22.82 ± 
1.18 % and 28.38 ± 0.84 %, N=10, *p<0.05) and expression 
(WT: 79.27 ± 10.29 %, n =10, 5XFAD: 39.28 ± 9.87 %, N=10, 
*p<0.05) in age-matched 6-month-old WT and 5XFAD mice. 
















Figure 2-4. Treatment with oligomeric Aβ1-42 activated 
primary cultured astrocytes In vitro  
(a) Representative immunoblots for GFAP in vehicle- and oA
β-treated primary cultured astrocytes from C57B/L6 p1 mice. 
(b) Densitometric analysis of immunoblots for GFAP (Vehicle: 
1.00 ± 0.181, N=4, oAβ: 1.586 ± 0.169, N=4, *p<0.05). The 











Figure 2-5. Astrocytes were activated via STAT3 
phosphorylation in vitro  
(a) Representative immunoblots for p-STAT3, STAT3, p-p65, 
p65, p-ERK and ERK for vehicle- and oAβ-treated primary 
cultured astrocytes from C57B/L6 p1 mice. (N = 4) (b) 
Densitometric analysis of immunoblots for p-STAT3 (Vehicle: 
1.00 ± 0.157, N=4, oAβ: 2.440 ± 0.454, N=4, *p<0.05), 
STAT3 (Vehicle: 1.00 ± 0.066, N=4, oAβ: 1.385 ± 0.079, 
N=4, *p<0.05), p-p65 (Vehicle: 1.00 ± 0.007, N=4, oAβ: 
0.963 ± 0.050, N=4), p65 (Vehicle: 1.00 ± 0.095, N=4, oAβ: 
1.063 ± 0.032, N=4), p-ERK (Vehicle: 1.00 ± 0.147, N=4, 
oAβ: 1.020 ± 0.076, N=4) and ERK (Vehicle: 1.00 ± 0.130, 
N=4, oAβ: 1.045 ± 0.140, N=4). The data are displayed as 















Figure 2-6. STAT3 phosphorylation was increased in the 
hippocampus of 6-month-old 5XFAD mice  
(a) Representative immunoblots for p-STAT3, STAT3, p-
ERK, ERK, p-p65 and p65 in the WT (N=7) and 5XFAD (N = 9) 
hippocampus. (b) Densitometric analysis of immunoblots for 
p-STAT3 (WT: 1.00 ± 0.166, N=7, 5XFAD: 5.312 ± 1.087, 
N=9, ***p<0.001), STAT3 (WT: 1.00 ± 0.049, N=7, 5XFAD: 
1.433 ± 0.081, N=9, **p<0.01), p-p65 (WT: 1.00 ± 0.083, 
N=7, 5XFAD: 0.924 ± 0.101, N=9), p65 (WT: 1.00 ± 0.055, 
N=7, 5XFAD: 1.024 ± 0.044, N=9), p-ERK (WT: 1.00 ± 
0.078, N=7, 5XFAD: 0.996 ± 0.057, N=9) and ERK (WT: 1.00 
± 0.072, N=7, 5XFAD: 1.054 ± 0.064, N=9). The data are 






















Figure 2-7. STAT3 phosphorylation was colocalized with 
astrocytes in the hippocampus of 6-month-old 5XFAD mice  
(a) Immunofluorescence for p-STAT3 and GFAP in the 
hippocampal dentate gyrus of both WT and 5XFAD mice (scale 
bar = 50 μm). (b) Colocalization of p-STAT3 and GFAP in the 
hippocampal dentate gyrus (p-STAT3-GFAP colocalization: 
86.02 ± 1.79%, N=5, p-STAT3 only: 13.97 ± 1.79%, N=5, 
*p<0.05). (c) Immunofluorescence for p-STAT3 and Iba-1, 
NeuN in the hippocampal dentate gyrus of 5XFAD mice (scale 































Figure 2-8. Stattic attenuated the activation of astrocyte by 
inhibition of STAT3 phosphorylation In vitro   
(a)Representative immunoblots for p-STAT3, STAT3 and 
GFAP from vehicle and 1 μM Stattic-treated time 
dependently in primary cultured astrocyte. (b) Densitometric 
analysis of immunoblots for p-STAT3 (Vehicle: 1.00 ± 0.000, 
N=3, 1h: 0.557 ± 0.036, N=3, *p<0.05, 3h: 0.564 ± 0.033, 
N=3, *p<0.05, 6h: 0.617 ± 0.097, N=3, *p<0.05, 12h: 0.914 
± 0.130, N=3), STAT3 (Vehicle: 1.00 ± 0.000, N=3, 1h: 
1.087 ± 0.033, N=3, 3h: 1.045 ± 0.071, N=3, 6h: 1.030 ± 
0.094, N=3, 12h: 0.842 ± 0.124, N=3), ratio of p-STAT3 per 
total STAT3 (Vehicle: 1.00 ± 0.000, N=3, 1h: 0.515 ± 0.049, 
N=3, ***p<0.001, 3h: 0.539 ± 0.004, N=3, ***p<0.001, 6h: 
0.592 ± 0.044, N=3, ***p<0.001, 12h: 1.090 ± 0.039, N=3) 
and GFAP (Vehicle: 1.00 ± 0.000, N=3, 1h: 0.778 ± 0.160, 
N=3, 3h: 0.612 ± 0.009, N=3, *p<0.05, 6h: 0.657 ± 0.079, 
N=3, 12h: 0.803 ± 0.046, N=3) in the vehicle and Stattic 



























Figure 2-9. Oral administration of Stattic restored the 
activation of astrocytes in the hippocampus of 6-month-old 
5XFAD mice   
(a) A time schedule for the Stattic administration and behavior 
testes with WT and 5XFAD mice is shown. (b) Representative 
immunoblots for p-STAT3, STAT3 and GFAP from WT and 
5XFAD mice that received vehicle or Stattic treatment. (N = 
6) (c) Densitometric analysis of immunoblots for p-STAT3 
(WT-V: 1.00 ± 0.110, N=6, WT-S: 1.716 ± 0.361, N=6, 
5XFAD-V: 11.273 ± 1.862, N=6, ***p<0.001, 5XFAD-S: 
6.155 ± 0.919, N=6, #p<0.05), STAT3 (WT-V: 1.00 ± 0.107, 
N=6, WT-S: 1.306 ± 0.134, N=6, 5XFAD-V: 1.590 ± 0.150, 
N=6, 5XFAD-S: 1.454 ± 0.299, N=6) and GFAP (WT-V: 1.00 
± 0.051, N=6, WT-S: 2.262 ± 0.679, N=6, 5XFAD-V: 5.131 
± 0.620, N=6, ***p<0.001, 5XFAD-S: 2.610 ± 0.242, N=6, 












Figure 2-10. Physiological characteristics of Stattic 
administrated mice  
(a) Line graph showing the body weights of WT and 5XFAD 
mice treated with vehicle or Stattic. (WT-V-day 1: 33.136 ± 
0.832, N=11, WT-V-day 2: 33.009 ± 0.809, N=11, WT-V-
day 3: 32.736 ± 0.736, N=11, WT-V-day 4: 32.000 ± 0.772, 
N=11, WT-V-day 5: 32.882 ± 0.814, N=11, WT-V-day 6: 
33.000 ± 0.804, N=11, WT-V-day 7: 32.500 ± 0.754, N=11, 
WT-V-day 8: 32.645 ± 0.650, N=11, WT-V-day 9: 32.764 ± 
0.614, N=11, WT-V-day 10: 32.473 ± 0.682, N=11, WT-V-
day 11: 32.373 ± 0.731, N=11, WT-V-day 12: 31.918 ± 
0.708, N=11, WT-V-day 13: 31.136 ± 0.962, N=11, WT-V-
day 14: 32.373 ± 0.644, N=11, WT-S-day 1: 30.345 ± 0.550, 
N=11, WT-S-day 2: 30.954 ± 0.460, N=11, WT-S-day 3: 
30.600 ± 0.434, N=11, WT-S-day 4: 30.181 ± 0.446, N=11, 
WT-S-day 5: 30.809 ± 0.527, N=11, WT-S-day 6: 30.645 ± 
0.508, N=11, WT-S-day 7: 30.418 ± 0.507, N=11, WT-S-day 
8: 30.327 ± 0.520, N=11, WT-S-day 9: 30.590 ± 0.525, 
N=11, WT-S-day 10: 30.763 ± 0.529, N=11, WT-S-day 11: 
30.400 ± 0.560, N=11, WT-S-day 12: 29.818 ± 0.516, N=11, 
WT-S-day 13: 29.790 ± 0.544, N=11, WT-S-day 14: 29.845 
± 0.570, N=11, 5XFAD-V-day 1: 31.640 ± 0.596, N=10, 
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5XFAD-V-day 2: 31.220 ± 1.235, N=10, 5XFAD-V-day 3: 
32.070 ± 0.512, N=10, 5XFAD-V-day 4: 31.700 ± 0.672, 
N=10, 5XFAD-V-day 5: 32.570 ± 0.635, N=10, 5XFAD-V-
day 6: 32.350 ± 0.562, N=10, 5XFAD-V-day 7: 32.390 ± 
0.723, N=10, 5XFAD-V-day 8: 32.540 ± 0.774, N=10, 
5XFAD-V-day 9: 32.990 ± 0.808, N=10, 5XFAD-V-day 10: 
32.100 ± 0.738, N=10, 5XFAD-V-day 11: 32.190 ± 0.708, 
N=10, 5XFAD-V-day 12: 31.920 ± 0.696, N=10, 5XFAD-V-
day 13: 31.67 ± 0.654, N=10, 5XFAD-V-day 14: 31.850 ± 
0.657, N=10, 5XFAD-S-day 1: 31.036 ± 0.740, N=11, 
5XFAD-S-day 2: 31.836 ± 0.714, N=11, 5XFAD-S-day 3: 
31.372 ± 0.628, N=11, 5XFAD-S-day 4: 30.900 ± 0.787, 
N=11, 5XFAD-S-day 5: 30.936 ± 0.821, N=11, 5XFAD-S-
day 6: 30.981 ± 0.621, N=11, 5XFAD-S-day 7: 31.127 ± 
0.613, N=11, 5XFAD-S-day 8: 30.981 ± 0.560, N=11, 
5XFAD-S-day 9: 31.436 ± 0.507, N=11, 5XFAD-S-day 10: 
31.072 ± 0.524, N=11, 5XFAD-S-day 11: 31.200 ± 0.516, 
N=11, 5XFAD-S-day 12: 30.618 ± 0.499, N=11, 5XFAD-S-
day 13: 30.418 ± 0.531, N=11, 5XFAD-S-day 14: 30.336 ± 
0.543, N=11). And bar graph showing brain weights (WT-V: 
477.300 ± 7.671, N=11, WT-S: 472.214 ± 9.812, N=11, 
5XFAD-V: 485.320 ± 8.960, N=10, 5XFAD-S: 468.200 ± 
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6.443, N=11). Bar graph showing the ratios of brain weight to 
body weight (WT-V: 14.491 ± 0.532, N=11, WT-S: 15.359 ± 
0.567, N=11, 5XFAD-V: 15.203 ± 0.330, N=10, 5XFAD-S: 


























Figure 2-11. Oral administration of Stattic restored the 
impairment of cognitive function in 6-month-old 5XFAD mice   
(a) A graph showing the alternation percentage in the T-
maze test after vehicle or Stattic oral administration to 5XFAD 
mice (WT-V: 72.727 ± 6.265, N=11, WT-S: 65.909 ± 9.091, 
N=11, 5XFAD-V: 45.500 ± 4.488, N=10, 5XFAD-S: 72.727 
± 5.281, N=11). (b) A graph showing the freezing time 
percentage at habituation (WT-V: 1.791 ± 0.602, N=11, WT-
S: 3.499 ± 0.836, N=11, 5XFAD-V: 2.237 ± 1.171, N=10, 
5XFAD-S: 4.608 ± 1.556, N=11), training (WT-V-1st: 24.121 
± 3.965, N=11, WT-V-2nd: 60.515 ± 5.350, N=11, WT-V-3rd: 
84.439 ± 4.756, N=11, WT-S-1st: 24.558 ± 4.725, N=11, 
WT-S-2nd: 60.006 ± 4.426, N=11, WT-S-3rd: 82.094 ± 
8.864, N=11, 5XFAD-V-1st: 37.100 ± 7.225, N=10, 5XFAD-
V-2nd: 60.600 ± 6.382, N=10, 5XFAD-V-3rd: 89.060 ± 4.753, 
N=10, 5XFAD-S-1st: 24.888 ± 2.272, N=11, 5XFAD-S-2nd: 
58.991 ± 4.540, N=11, 5XFAD-S-3rd: 89.442 ± 3.410, N=11) 
and expression (WT-V: 78.288 ± 5.453, N=11, WT-S: 81.985 
± 4.460, N=11, 5XFAD-V: 29.814 ± 7.485, N=10, 5XFAD-S: 
87.624 ± 3.825, N=11) in the contextual fear conditioning 
test after vehicle or Stattic oral administration to 5XFAD mice. 






















Figure 2-12. Oral administration of Stattic restored the 
activation of astrocytes in the hippocampus of 6-month-old 
5XFAD mice  
(a) Immunofluorescence for p-STAT3 and GFAP in the 
hippocampal dentate gyrus of both WT and 5XFAD mice that 
received vehicle or Stattic treatment (scale bar = 100 μm). 
(N ≥ 9) (b) Quantification of immunoblots for p-STAT3 
(WT-V: N.D. N=11, WT-S: N.D. N=11, 5XFAD-V: 1.000 ± 
0.110, N=9, 5XFAD-S: 0.456 ± 0.049, N=10, **p<0.01), p-
STAT-GFAP colocalization (WT-V: N.D. N=10, WT-S: N.D. 
N=10, 5XFAD-V: 1.000 ± 0.079, N=9, 5XFAD-S: 0.530 ± 
0.054, N=10, **p<0.01) and GFAP (WT-V: 1.000 ± 0.051, 
N=10, WT-S: 1.362 ± 0.092, N=10, 5XFAD-V: 5.116 ± 
0.333, N=9, ***p<0.01, 5XFAD-S: 3.158 ± 0.307, N=10, 














Figure 2-13. Oral administration of Stattic restored the 
number of processes of astrocytes in the hippocampus of 6-
month-old 5XFAD mice  
(a) Reconstructed images showing a cross-section along the 
X-Z axis from a confocal Z-stack; concentric circles are 
spaced at 10 μm. (b) Quantification of the number of 
intersections between processes and each circle (WT-V: 5 μ
m; 9.166 ± 0.257, 10 μm; 16.788 ± 0.378, 15 μm; 21.788 
± 0.492, 20 μm; 16.300 ± 0.580, 25 μm; 7.266 ± 0.632, 
30 μm; 1.566 ± 0.367, 35 μm; 0.088 ± 0.064, 40 μm; 
0.000 ± 0.000,N=5, WT-S: 5 μm; 7.730 ± 0.461, 10 μm; 
14.947 ± 1.523, 15 μm; 19.127 ± 2.091, 20 μm; 15.344 ± 
2.097, 25 μm; 7.894 ± 1.950, 30 μm; 3.036 ± 1.006, 35 μ
m; 0.622 ± 0.319, 40 μm; 0.066 ± 0.044,N=5, 5XFAD-V: 5 
μm; 11.904 ± 0.300, 10 μm; 28.992 ± 0.636, 15 μm; 
41.904 ± 1.521, 20 μm; 40.238 ± 2.412, 25 μm; 27.468 ± 
1.975, 30 μm; 11.206 ± 1.473, 35 μm; 2.531 ± 0.709, 40 
μm; 0.357 ± 0.156, N=5, ***p<0.001, 5XFAD-S: 5 μm; 
9.814 ± 0.195, 10 μm; 19.981 ± 0.571, 15 μm; 25.444 ± 
1.167, 20 μm; 20.833 ± 1.212, 25 μm; 10.981 ± 1.033, 30 
μm; 3.388 ± 0.540, 35 μm; 0.351 ± 0.119, 40 μm; 0.018 
± 0.018, N=5, ###p<0.001. The data are displayed as the 
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Figure 2-14. Oral administration of Stattic restored the 
volume of astrocytes in the hippocampus of 6-month-old 
5XFAD mice  
(a) Reconstructed images of GFAP with IMARIS (scale bar = 5 
μm) (b) Quantification of the volume of astrocytes (WT-V: 
224.115 ± 9.101, N=5, WT-S: 221.611 ± 12.469, N=5, 
5XFAD-V: 687.829 ± 60.310, N=5, ***p<0.01, 5XFAD-S: 
272.424 ± 14.415, N=5, ###p<0.001). The data are displayed 


















Figure 2-15. Systemic administration of Stattic restored the 
decrease in the number of tripartite synapses in 6-month-old 
5XFAD mice (A) Immunofluorescence for p-STAT3 and GFAP 
in the hippocampal DG of both WT and 5XFAD mice that were 
treated with vehicle or Stattic (scale bar = 10 μm). (F) 
Reconstructed images showing a cross-section along the X-Z 
axis from a confocal Z-stack image from both WT and 5XFAD 
mice that were treated with vehicle or Stattic (scale bar = 10 
μm). (G) Quantification of the colocalization of PSD-95 and 
GFAP in the reconstructed cross-section images in the WT and 
5XFAD hippocampal DG of mice given vehicle or stattic. (WT-
V: 33.625 ± 1.068, N=12, WT-S: 32.600 ± 0.795, N=12, 
5XFAD-V: 13.516 ± 0.721, N=12, ***p<0.001, 5XFAD-S: 
30.533 ± 5.488, N=12, ###p<0.001), Data are displayed as 












Figure 2-16. Oral administration of Stattic reduced the 
number of Aβ plaques in the hippocampus of 5XFAD mice  
(a) Thioflavin S staining was performed in the hippocampal 
dentate gyrus (scale bar = 100 μm). (b) Quantification of the 
number of Aβ plaques (WT-V: N.D., N=10, WT-S: N.D., N=10, 
5XFAD-V: 26.800 ± 3.508, N=10, ***p<0.01, 5XFAD-S: 
20.700 ± 2.108, N=10, #p<0.05). The data are displayed as 

















Figure 2-17. Oral administration of Stattic reduced the 
protein level of Aβ in the hippocampus of 5XFAD mice  
(c) Representative immunoblots showing Aβ. (d) 
Densitometric analysis of immunoblots of Aβ (WT-V: N.D. , 
N=6, WT-S: N.D. , N=6, 5XFAD-V: 1.000 ± 0.149, N=6, 
***p<0.01, 5XFAD-S: 0.586 ± 0.066, N=6, #p<0.05). The 

















Figure 2-18. Oral administration of Stattic reduced BACE1 
expression in the hippocampus of 5XFAD mice   
(a) Representative immunoblots showing BACE1 (b) 
Densitometric analysis of immunoblots of BACE1 (WT-V: 
1.000 ± 0.028, N=6, WT-S: 1.342 ± 0.209, N=6, 5XFAD-V: 
2.255 ± 0.224, N=6, ***p<0.01, 5XFAD-S: 1.503 ± 0.104, 





The novel functions of astrocytes in memory formation have 
been extensively studied in recent decades. Astrocytes 
increase the number of mature and functional synapses by 
releasing soluble molecules, such as thrombospondin and 
cholesterol, to regulate synaptic formation [149]. In addition, 
astrocytes have been reported to regulate synaptic elimination 
and spine morphology across brain development [150]. 
Astrocytes express neurotransmitter receptor G-protein 
coupled receptors (GPCRs) [151]. However, the binding of 
neurotransmitters to the receptors does not generate action 
potential in these cells, but rather increases the intracellular 
calcium concentration, causing gliotransmitter release in a 
calcium-dependent manner [152]. The released 
gliotransmitters can bind to pre- or postsynaptic receptors to 
regulate neuronal excitability and synaptic transmission. 
Glutamate released from astrocytes binds to presynaptic 
NMDAR to promote neurotransmitter release, while ATP 
released from astrocytes suppresses synaptic transmission. In 
addition, D-serine regulates postsynaptic NMDAR as an 
endogenous coagonist. Astrocyte-specific knockout animal 
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models such as GPCR or inositol 1,4,5 – triphosphate receptor 
type 2 (IP3R2) knockout animals, display a lack of calcium 
signaling in astrocytes and altered NMDAR-dependent LTP 
and long-term memory formation [153].  Recently, reactive 
astrocytes were reported to be significantly increased in a 
hippocampal dentate zyrus region in a hippocampus-
dependent cognitive impairment model [154].  
Astrocytes have been classified into A1 type and A2 type 
according to their genetic expression pattern. A1-type 
astrocytes have neurotoxic effects whereas A2-type 
astrocytes have neuroprotective effects. In neurodegenerative 
disorders such as AD and PD, more type A1-astrocytes than 
type A2-astrocytes are detected in the brain [73, 75, 155]. 
The astrocytes morphologically classified as type I, II and III 
are not fully understood regarding the function of each type of 
astrocyte in the CNS, as specific genetic and protein markers 
for each type of astrocyte have not been determined to date. 
Another problem resides in the in vitro morphology of 
astrocytes. The morphological types of astrocytes are 
identified with GFAP immunofluorescence staining in an in 
vivo system [156]. However, astrocytes have a process-
bearing morphology in vitro. Even though single-cell gene 
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expression analysis techniques have been developed, the 
morphological categorization of astrocytes in vitro remains 
limited.  
Since AD pathologies are the consequence of neuronal death, 
search for mechanisms and therapeutic approaches have been 
neurocentric until a recent time [157]. However, the 
importance of nonneuronal cells, such as astrocytes, is now 
largely established and opened new research approach that 
aim at better understanding of the pathology of the disease as 
well as characterizing new cellular and molecular targets for 
therapeutics development [158, 159].  
Astrocytes are determined to reside in three major states, i.e., 
the resting, the reactive and the active state. Astrocytes that 
are involved in memory formation are defined as active 
astrocytes, which are different from reactive astrocytes, 
according to several reports [160]. Astrocytes reveal changes 
in their morphology and transcription according to their status 
[75]. Astrocytes release various gliotransmitter including 
glutamate, GABA, D-serine, ATP, cytokines and proBDNF 
[161, 162]. 
Reactive state of astrocytes was described to be significantly 
increased at dentate gyrus region in the hippocampus to a 
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hippocampal-dependent cognitive impairment model [154]. It 
has been recently reported that the reactive astrocytes 
abnormally produce GABA by monoamine oxidase-B (MAO-B) 
and aberrantly release GABA through the bestrophin 1 channel 
in the dentate gyrus of APP/PS1 mice [163]. Administration 
with a newly developed reversible MAO-B specific inhibitor, 
KDS2010, significantly attenuated increased astrocytic GABA 
release and astrogliosis, enhancing synaptic transmission, and 
rescued learning and memory impairments in APP/PS1 mice 
[164].  
Traditionally, neurons are thought to be the only cell type that 
expresses BACE1 and is capable of producing Aβ. Recent 
studies have demonstrated that astrocytes also express BACE1 
and can produce Aβ under stressful conditions [165]. Secreted 
factors from reactive astrocytes, such as cytokines promote 
APP and BACE1 protein expression on neurons [165]. Not only 
neurons but also astrocytes and microglia are known to express 
APP, BACE1 and γ-secretase subunits, such as PS1, PS2, 
PEN2 and NCT, in the CNS [166].  
Recently, it has been reported that the astrocyte-specific 
STAT-3 deleted APP/PS1 mice displayed the decreased 
activation of pro-inflammatory cytokine and lower dystrophic 
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neurite burden, and were largely protected from cerebral 
network imbalance. In addition, STAT3 deletion in astrocytes 
significantly ameliorated the impairment of cognitive function 
in APP/PS1 mice [167]. These results described above were 
obtained in APP/PS1 mice of 8 – 11 months when the 
reduction in neuronal activity was observed compared to WT 
mice. However, my results showed that reactive state of 
astrocytes in the hippocampus were significantly increased 
via STAT3 phosphorylation in the early stage of AD when 
neuronal loss was not attended. In addition, the activation of 
the STAT3 pathway in astrocytes promotes the expression of 
cytoskeletal proteins, such as GFAP and vimentin, and the 
secretion of cytokines or chemokines, such as TGFβ, TNF-⍺, 
IL-1β, INF-γ, IL-6 and CCL2 [168]. Astrocytes and 
microglia have the potential to clear Aβ in the CNS via 
phagocytic activity. Secreted factors from astrocytes affect 
the phagocytic activity of astrocytes and microglia [169]. 
These studies suggest that the control of astrocyte reactivity 
is an option for therapeutic strategies for AD. 
In recent studies, novel AD therapeutic strategies regulating 
the JAK / STAT3 axis, one of the pathways leading to reactive 
state of astrocytes were established. These strategies 
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improved the impairment of cognitive function and neuronal 
activity in an AD mouse model [170, 171].  
In this study, I focused on the pathological roles of reactive 
astrocytes in the cognitive function impairments and 
investigated the pathways involved in activating astrocytes 
from the resting state to the reactive state in primary cultured 
astrocytes treated with oAβ and in the hippocampus of 6-
month-old 5XFAD mice. Six-month-old 5XFAD mice, which 
displayed an increase in the protein level of GFAP in the 
hippocampus and impairments of cognitive function, did not 
show a significant difference in the neuronal marker or 
synaptic proteins expression compared with the levels 
observed in age-matched WT mice. These results indicate that 
the control of reactive astrocytes could be one of important 
innovative factors for the rescue of cognitive dysfunction in 
6-month-old 5XFAD mice. However, the synaptic function of 
neurons are not fully explained with neuronal loss or 
expression of synaptic proteins as PSD-95 and synaptophysin. 
The neuronal electronic function is analyzed with the flow of 
ions as amplitude, frequency, LTP and LDT by the 
electrophysiology studies. It is might cause the cognitive 
impairment in 6-month-old 5XFAD mice by The neuronal 
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electronic function. In addition, I found that treatment with 
oAβincreased the protein level of p-STAT3 and GFAP in 
primary cultured astrocytes. Stattic attenuated p-STAT3 and 
GFAP protein levels in primary cultured astrocytes. 
Furthermore, the systemic administration of Stattic reversed 
the morphological features of reactive astrocytes and the 
impairments cognitive function by reducing Aβ production 
via BACE1 expression in 5XFAD mice. Systemic 
administration of Stattic could not be astrocyte-specific. 
However, astrocytes were thought to be more affected by 
Stattic than other cell types such as neurons and microglia, 
because GFAP, a well-known astrocyte marker protein was 
shown to be colocalized with more than approximately 80% of 
p-STAT3 in 6-month-old 5XFAD mice. Neurons and 
microglia were colocalized less than 5%. These results 
indicated that the transition of reactive astrocytes to resting-
state cells via inhibiting STAT3 phosphorylation may be a 
novel therapeutic strategy in AD. The results of Chapter 2 are 
summarized in Graphical Summary as below. 
Taken together, my results suggest that the inhibition of 
STAT3 phosphorylation rescues the astrocytes of reactive 
state into the cells of resting state in the hippocampal dentate 
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gyrus. Furthermore, my results describe a relationship 
between the regulation of astrocyte activity and cognitive 
functions. A drug that specifically inhibits STAT3 
phosphorylation in astrocytes may be a novel therapeutic 
strategy before neuronal loss is observed.  
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Graphical Summary: Chapter 2 
The alteration of molecular and morphological change in the 
reactive astrocytes after memory induction. The pathological 







Memory induction by the contextual fear conditioning test in 
mice activates astrocytes into a memory induction state. The 
memory induction state of astrocytes has different 
characteristics than resting and reactive states, such as 
decreased GFAP expression and increased EAAT2 and Cx43 
expression, for molecular changes and promoted the number 
of processes and the number of interaction between astrocytic 
processes and neuronal post-synapses. Intriguingly, even in  
astrocytic loss in the hippocampus, mice showed normal 
short-term memory but impaired long-term memory. These 
results indicate that astrocytes are essential for long-term 
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memory formation; however astrocytes are applied for short-
term memory formation. In an AD mouse model, reactive 
astrocytes are activated by Aβ via STAT3 phosphorylation. 
Reactive astrocytes showed a decrease in the number of 
interactions between astrocytic processes and neuronal 
dendritic spines, even though reactive astrocytes have more 
processes than memory-induced astrocytes. For long-term 
memory formation, the number of astrocyte - neuron 
interactions at the synapse is important. In addition, reactive 
astrocytes are thought to be involved in the production of Aβ 
in the hippocampus in AD mouse model. 
In conclusion, astrocytes play an essential role in long-term 
memory by physically interacting with dendritic spines. 
Reactive astrocytes activated via the STAT3 pathway alter 
astrocyte – neuron interactions and cause cognitive 
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중추신경계에서 성상교세포의 다양한 역할들이 보고되어 왔다. 성상교
세포는 잠재적으로 활성화 상태와 휴지기 상태의 두 가지의 상태로 변
화할 수 있는 능력이 있다. 활성화 성상교세포는 돌기의 두께와 그 수가 
증가하고, 세포체 부피의 증가가 특징적으로 나타난다. 또한, 신경교 섬
유질 산성단백질 (glial fibrillary acidic protein: GFAP)과 같은 단
백질 발현의 증가나 유전자 발현의 변화가 분자적 변화로 나타난다. 하
지만, 성상교세포에서 기억을 유도하는 과정 중에 이러한 즉각적인 형태
학적, 분자적 변화는 아직 연구가 부족한 상태이다. 알츠하이머병을 포
함한 퇴행성신경계질환의 발병 기전에 있어 활성화 상태의 성상교세포
의 병리생리학적 역할은 매우 중요한 의미가 있을 것이라 생각된다. 그
러나 퇴행성신경계질환이 진행되는 동안 휴지기 상태의 성상교세포가 
활성화 상태로 전환되는 구체적인 작용 원리의 이해는 여전히 명백하게 
밝혀져 있지 않다. 본 연구에서는 Fvb/n 마우스 뇌내 해마에 존재하는 
성상교세포를 공포 상황 조건화 실험 (contextual fear conditioning) 
을 통해 기억 유도를 하였다. 이후 기억 유도한 성상교세포의 형태학적 
분자적 변화를 분석 하였다. 공포 상황 조건화 실험 1시간 후, 타입 2
와 타입 3 성상교세포가 활성화와 휴지 상태의 특징이 아닌, 돌기의 수
가 증가하고, 신경교 섬유질 산성단백질의 발현이 감소되는 새로운 상태
로 관측되었다. 또한, 흥분성 아미노산 운반자 2 (excitatory amino 
acid transporter 2: EAAT2)의 단백질 발현이 공포 상황 조건화 후 
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1시간 에서 24시간까지 단백질 발현이 증가하였지만, 흥분성 아미노산 
운반자 1은 변화가 없는 것이 확인되었다. 공포 상황 조건화 24시간 후 
코넥신 43 (Connexin 43: Cx43) 단백질의 발현의 증가가 확인되었다. 
성상교세포 특이적 독성 물질인, 엘-알파-아미노아디페이트 (L-α-
aminoadipate: LAA)가 뇌내 해마에 처리된 마우스에서 인지능력의 
저하가 확인되었다.  초대 배양 성상교세포에 다량체 아밀로이드 펩티드 
(oAβ)를 처치하는 방법과 6개월령 알츠하이머병 동물 모델 5XFAD의 
해마 부위에서 어떤 신호전달 경로가 연관되어 있는지 확인하였다. 신경
교 섬유질 산성단백질 발현의 증가를 통해서 초대 배양 성상교세포의 
다량체 아밀로이드 펩티드 처치는 활성화 성상교세포의 증가의 유도함
을 확인하였다. 이러한 초대 배양 성상교세포의 활성화는 신호변환자-
전사활성자 3 (signal transducer and activator of transcription: 
STAT3)의 인산화를 통해 증가하였다. 초대 배양 성상교세포 활성화와 
6개월령 알츠하이머동물 모델의 인지능력 저해를 신호변환자-전사활성
자 3 인산화 억제제 스테틱(Stattic)의 전신 적용이 완화시킴을 확인하
였다. 위 결과를 종합하면, 해마 기반 공포 상황 조건화 실험에 의해 기
억 유도된 성상교세포는 새로운 형태를 보이며 이를, 기억 유도 상태가 
되었다. 알츠하이머병 뇌 내에서 활성화 상태의 성상교세포로 존재함으
로 이러한 기억 유도 상태 성상교세포는 정상적이지 않을 것이다. 알츠
하이머병 뇌의 활성화 성상교세포는 신호변환자-전사활성자 3 인산화를 
통해서 나타나며, 학습과 기억력의 저하가 신호변환자-전사활성자 3 인
산화 억제제를 통해서 완화되었다. 이는 신호변환자-전사활성자 3 인산
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화 억제제를 통한 성상교세포의 활성화 조절이 알츠하이머병의 인지능
력저하의 새로운 치료 전략으로 제시될 가능성을 보였다.  
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